2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association

Abstract

In May 2023, the Committee of Clinical Practice Guidelines of the Korean Diabetes Association published the revised clinical practice guidelines for Korean adults with diabetes and prediabetes. We incorporated the latest clinical research findings through a comprehensive systematic literature review and applied them in a manner suitable for the Korean population. These guidelines are designed for all healthcare providers nationwide, including physicians, diabetes experts, and certified diabetes educators who manage patients with diabetes or individuals at risk of developing diabetes. Based on recent changes in international guidelines and the results of a Korean epidemiological study, the recommended age for diabetes screening has been lowered. In collaboration with the relevant Korean medical societies, recently revised guidelines for managing hypertension and dyslipidemia in patients with diabetes have been incorporated into this guideline. An abridgment containing practical information on patient education and systematic management in the clinic was published separately.

Effect of Adding Apolipoprotein B Testing on the Prevalence of Dyslipidemia and Risk of Cardiovascular Disease in the Korean Adult Population

“…The prevalence of dyslipidemia identified using either traditional lipid tests or ApoB in this study (44.9%) was more aligned with the KNHANES findings [ 12 ]. The prevalence reported by KNHANES includes subjects treated with statins, whose lipid profile results fell below the cutoff due to the statin treatment [ 2 , 12 , 29 , 30 ]. Meanwhile, in the present study, clinical information on subjects, including statin treatment, was limited, which might result in lipid profile results below the cutoff.…”

SGLT2i impact on HCC incidence in patients with fatty liver disease and diabetes: a nation-wide cohort study in South Korea

“…In South Korea, OHA is prescribed according to the insurance coverage criteria of the National Health Insurance Service. The insurance coverage criteria were based on the patient's glycemic control status, as represented by hemoglobin A1c(HbA1c) 33 . Thus, the number of prescribed OHA or insulin use was closely related to the glycemic control status in each patient.…”

Uncontrolled hypertension is associated with an increased risk of end-stage renal disease in patients with type 2 diabetes who underwent postpercutaneous coronary intervention: A nationwide population-based study

“…For individuals with T2DM who have one or more risk factors for CVD, existing CVD, CKD stage 3-5, or asymptomatic organ damage, a BP target of less than 130/80 mmHg is advised [3][4][5] . However, insufficient data exist on the recommended BP target to reduce progression to ESRD in individuals with coronary artery disease (CAD) and T2DM.…”

“…The Korean Society of Hypertension and the Korean Diabetes Association suggest maintaining BP below 140/90 mmHg in people with type 2 diabetes who do not have additional CVD risk factors or CVD. For individuals with T2DM who have one or more risk factors for CVD, existing CVD, CKD stage 3-5, or asymptomatic organ damage, a BP target of less than 130/80 mmHg is advised 3–5 . However, insufficient data exist on the recommended BP target to reduce progression to ESRD in individuals with coronary artery disease (CAD) and T2DM.…”